Atrial fibrillation: Therapeutic potential of atrial K + channel blockers
Authors:
- 1 August 2017
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 176, 13-21
Abstract
No abstract availableKeywords
This publication has 120 references indexed in Scilit:
- TWIK1, a unique background channel with variable ion selectivityProceedings of the National Academy of Sciences, 2012
- Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conferenceEP Europace, 2011
- A Specific Two-pore Domain Potassium Channel Blocker Defines the Structure of the TASK-1 Open PoreJournal of Biological Chemistry, 2011
- Carvedilol targets human K2P3.1 (TASK1) K+leak channelsBritish Journal of Pharmacology, 2011
- Common variants in KCNN3 are associated with lone atrial fibrillationNature Genetics, 2010
- New Pharmacological Strategies for the Treatment of Atrial FibrillationAnnals of Noninvasive Electrocardiology, 2009
- Pathology‐specific effects of the IKur/Ito/IK,ACh blocker AVE0118 on ion channels in human chronic atrial fibrillationBritish Journal of Pharmacology, 2008
- Generation of a constitutive Na+‐dependent inward‐rectifier current in rat adult atrial myocytes by overexpression of Kir3.4The Journal of Physiology, 2007
- Early electrical remodeling in rabbit pulmonary vein results from trafficking of intracellular SK2 channels to membrane sitesCardiovascular Research, 2007
- Regional and tissue specific transcript signatures of ion channel genes in the non‐diseased human heartThe Journal of Physiology, 2007